品牌现货直购
供应商:我要出现这里






查看所有供应商和价格请点击:

761423-87-4生产厂家

761423-87-4价格

761423-87-4

761423-87-4结构式
761423-87-4结构式
  • 常用中文名:伊格列净
  • 常用英文名:Ipragliflozin
  • CAS号:761423-87-4
  • 分子式:C21H21FO5S
  • 分子量:404.452
  • 相关类别: 信号通路 跨膜转运 SGLT
  • 发布时间:2018-02-14 08:00:00
  • 更新时间:2024-01-02 14:56:12
  • Ipragliflozin (ASP1941)是高活性SGLT2选择性抑制剂,IC50为2.8 nM,对SGLT1/3/4/5/6几乎无活性。

化源商城直购

中文名 伊格列净
英文名 (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
英文别名 D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-
ASP1941
UNII-3N2N8OOR7X
ASP 1941
(1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol
Suglat
Ipragliflozin
描述 Ipragliflozin (ASP1941)是高活性SGLT2选择性抑制剂,IC50为2.8 nM,对SGLT1/3/4/5/6几乎无活性。
相关类别
参考文献

[1]. Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20(10):3263-79.

[2]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701.

[3]. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36.

[4]. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44.

[5]. Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55.

[6]. Yoshikawa T, et al. Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. Hypertens Res. 2017 Jul;40(7):646-651.

[7]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.

密度 1.5±0.1 g/cm3
沸点 628.8±55.0 °C at 760 mmHg
分子式 C21H21FO5S
分子量 404.452
闪点 334.1±31.5 °C
精确质量 404.109375
PSA 118.39000
LogP 5.59
外观性状 粉末
蒸汽压 0.0±1.9 mmHg at 25°C
折射率 1.684
储存条件 -20℃

~88%

761423-87-4结构式

761423-87-4

文献:Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 13 ;

~97%

761423-87-4结构式

761423-87-4

文献:Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd. Patent: EP2105442 A1, 2009 ; Location in patent: Page/Page column 15 ;

~%

761423-87-4结构式

761423-87-4

文献:Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

~%

761423-87-4结构式

761423-87-4

文献:Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

~%

761423-87-4结构式

761423-87-4

文献:Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279

~%

761423-87-4结构式

761423-87-4

文献:Bioorganic and Medicinal Chemistry, , vol. 20, # 10 p. 3263 - 3279